Trial Profile
AP5346 [ProLindac; Access Pharmaceuticals] for recurrent/unresectable squamous cell carcinoma of the head and neck: a pilot study with clinical and biological endpoints
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs AP 5346 (Primary) ; Oxaliplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 18 Jan 2006 New trial record.